↓ Skip to main content

Metformin and Autoimmunity: A “New Deal” of an Old Drug

Overview of attention for article published in Frontiers in immunology, June 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news
1 news outlet
twitter
52 X users

Citations

dimensions_citation
134 Dimensions

Readers on

mendeley
158 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Metformin and Autoimmunity: A “New Deal” of an Old Drug
Published in
Frontiers in immunology, June 2018
DOI 10.3389/fimmu.2018.01236
Pubmed ID
Authors

Francesco Ursini, Emilio Russo, Gianluca Pellino, Salvatore D’Angelo, Agostino Chiaravalloti, Giovambattista De Sarro, Roberto Manfredini, Roberto De Giorgio

Abstract

Metformin (dimethyl biguanide) is a synthetic derivative of guanidine, isolated from the extracts of Galega officinalis, a plant with a prominent antidiabetic effect. Since its discovery more than 50 years ago, metformin represents a worldwide milestone in treatment of patients with type 2 diabetes (T2D). Recent evidence in humans indicates novel pleiotropic actions of metformin which span from its consolidated role in T2D management up to various regulatory properties, including cardio- and nephro-protection, as well as antiproliferative, antifibrotic, and antioxidant effects. These findings, together with ground-breaking studies demonstrating its ability to prolong healthspan and lifespan in mice, provided the basis for defining metformin as a potential antiaging molecule. Moreover, emerging in vivo and in vitro evidence support the novel hypothesis that metformin can exhibit immune-modulatory features. Studies suggest that metformin interferes with key immunopathological mechanisms involved in systemic autoimmune diseases, such as the T helper 17/regulatory T cell balance, germinal centers formation, autoantibodies production, macrophage polarization, cytokine synthesis, neutrophil extracellular traps release, and bone or extracellular matrix remodeling. These effects may represent a powerful contributor to antiaging and anticancer properties exerted by metformin and, from another standpoint, may open the way to assess whether metformin can be a candidate molecule for clinical trials involving patients with immune-mediated diseases. In this article, we will review the available preclinical and clinical evidence regarding the effect of metformin on individual cells of the immune system, with emphasis on immunological mechanisms related to the development and maintenance of autoimmunity and its potential relevance in treatment of autoimmune diseases.

X Demographics

X Demographics

The data shown below were collected from the profiles of 52 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 158 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 158 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 22 14%
Researcher 15 9%
Student > Ph. D. Student 14 9%
Student > Bachelor 13 8%
Student > Doctoral Student 7 4%
Other 28 18%
Unknown 59 37%
Readers by discipline Count As %
Medicine and Dentistry 30 19%
Biochemistry, Genetics and Molecular Biology 17 11%
Immunology and Microbiology 16 10%
Agricultural and Biological Sciences 12 8%
Pharmacology, Toxicology and Pharmaceutical Science 7 4%
Other 14 9%
Unknown 62 39%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 39. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 April 2024.
All research outputs
#1,075,556
of 25,830,005 outputs
Outputs from Frontiers in immunology
#947
of 32,460 outputs
Outputs of similar age
#22,849
of 344,139 outputs
Outputs of similar age from Frontiers in immunology
#34
of 744 outputs
Altmetric has tracked 25,830,005 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 32,460 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 344,139 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 744 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.